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Vascular endothelial cell growth factor (VEGF) is now known to
be a key factor in the induction of angiogenesis in many tumour
types (reviewed in Neufeld et al, 1999). VEGF has for several
years been known to exist as several isoforms arising from differ-
ential splicing of the mRNA. Human VEGF mRNA is transcribed
from 8 exons and alternatively spliced into at least five variants
which give rise to mature monomers of 121, 145, 165, 189 and 206
amino acids (Tischer et al, 1991). Recently, a new splice variant of
183 amino acids has been identified (Lei et al, 1998). While it has
also been known for several years that the isoforms show little
difference in their affinity for the VEGF receptors, flt-1 and KDR,
it is known that they differ in the affinity with which they bind to
heparin and heparin-like molecules. Thus, the larger isoforms (165
and 189) bind tightly to heparin, while the smaller 121 isoform
does not (Houck et al, 1992). It has been reported that the 121
amino acid isoform is a 100-fold less potent mitogen than the 165
or 189 isoforms (Keyt et al, 1996), but this has been questioned by
others (Gitay-Goren et al, 1996; Siemeister et al, 1996).
Of the isoforms, expression of VEGF206 is rare, occurring
predominantly in fetal liver (Houck et al, 1991). In contrast, the
mRNAs corresponding to the 121, 165, and 189 isoforms are
found in most normal tissues, VEGF121 and VEGF165 predomi-
nate in normal tissue (Houck et al, 1991). Increasingly, however,
exceptions to this uniform pattern of variant mRNA expression are
emerging. These include differential patterns of expression in
tissues (Carmeliet et al, 1999) as well as activation-dependent cell-
specific expression of VEGF isoforms. In this regard, VEGF189
expression has been shown to be dominant in normal lung
(Cheung et al, 1998) and the 183 isoform predominates in heart
(Lei et al, 1998). VEGF206 has been detected in skin and HMC-1
mast cells after a prolonged stimulation with phorbol-12-myris-
tate-13-acetate and the ionophore A23187 (Grutzkau et al, 1998).
Selective knockout of the 165 and 189 isoforms using cre/lox
recombinant technology in mice has shown that the higher molec-
ular weight isoforms play a role in development of the heart pre-
and post-natally. Thus, mice lacking these isoforms show impaired
myocardial angiogenesis (Carmeliet et al, 1999).
All of the variant VEGF proteins are assumed to be secreted in
that they share the same secretion signal sequence of 26 amino
acids. Compared with VEGF121, VEGF165 has an insertion of 44
amino acids rich in basic residues encoded by exon 7 and
VEGF189 has a further insertion of 24 amino acids highly
enriched in basic residues encoded by exon 6a. Despite this, little
is known concerning the in vitro activities of the different
isoforms. While the physiological significance of the differential
splicing remains to be determined, we have examined the effects
of the differential splicing on tumorigenesis. Several studies have
reported transfection of VEGF into a range of carcinoma lines,
followed by examination of the effect on tumorigenesis (reviewed
in Bicknell et al, 1997). These studies uniformly concur that
VEGF expression enhances tumour growth and some conclude
that it also enhances the tumour vascular density. In the case of the
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effect on hormone dependence or tamoxifen sensitivity (Zhang et
al, 1995). However, in none of these studies has the effect of
expression of the 121, 165 and 189 isoforms on in vivo growth of
capillary vessels and tumours been directly compared. This paper
describes such a comparison.
MATERIALS AND METHODS
Vector construction
VEGF expression plasmids were constructed by inserting full-
length complementary DNA (cDNA) into pcDNA1NEO
(Invitrogen) in which the cytomegalovirus (CMV) promoter drives
constitutive expression. The cDNAs of VEGF165 (a gift of H
Weich, Braunschweig, Germany) and VEGF189 (a gift of J
Abraham, Scios Nova, USA) were cloned as BamH 1-EcoR V and
BamH 1 fragments respectively into the compatible sites of
pcDNA1NEO. The resulting constructs were propagated in
Escherichia coli strain MC1061/P3. The 5¢ untranslated regions of
the VEGF121 and 165 cDNAs were indentical and very similar to
that of the VEGF189.
Preparation of VEGF overexpressing MCF-7 cells
VEGF165 and VEGF189 overexpressing MCF-7 cells were
prepared essentially as described for the preparation of VEGF121
overexpressing cells (Zhang et al, 1995). Clones were initially
screened by ribonuclease protection analysis. The conditioned
media from clones overexpressing VEGF message was then
assayed for VEGF protein expression by enzyme-linked
immunosorbent assay (ELISA). Serum-free medium was condi-
tioned for 48 h by confluent cultures. Suramin (Zeneca
Pharmaceuticals Alderly Edge, UK) was added to a concentration
of 1 mM 4 h before harvesting to displace cell bound VEGF.
ELISA was performed using a ‘Quantikine’ kit (R and D Systems,
Abingdon, UK) according to manufacturer’s instructions.
Effect of VEGF121 and VEGF165 on microvascular
endothelial cell growth in vitro
On day –1, human dermal microvascular endothelial cells
(HDMECs) were seeded into collagen-coated 6-well plates at
2000 cells cm2 in essential balanced medium (EBM) (Clonetics)
containing epidermal growth factor (EGF) (10 ng ml–1) and
endothelial cell growth supplement (30 mg ml–1). On day 0 the
cells were counted and media in the remaining wells changed to
EBM containing 5% fetal calf serum (FCS) and 8 ng ml–1
VEGF121 or VEGF165 (both from R and D Systems, Minneapolis
MN, USA). Cells were re-fed every other day or released by treat-
ment with trypsin and counted in a Coulter counter (Coulter
Electronics).
Angiogenesis in vivo: rabbit cornea assay
The cornea is an avascular and transparent tissue and growing
capillaries may be easily monitored and quantitated by stereomi-
croscopic examination. Corneal assays were performed in female
New Zealand albino rabbits (Charles River, Calco, Como, Italy) as
described (Zhang et al, 1995) and in accordance to European
Union animal care and welfare (EU law N. 86/609). MCF7 cells
overexpressing the different VEGF isoforms were detached and
resuspended at the density of 2.5 ´ 105 cells per 5 ml. The cell
suspension in a volume of 5 ml was implanted into a corneal
micropocket. Subsequent daily observation of the implants was
made with a slit lamp stereomicroscope without anaesthesia. An
angiogenic response was scored positive when budding of vessels
from the limbal plexus occurred after 3–4 days and capillaries
progressed to reach the implanted pellet according to the scheme
previously reported. The number of positive implants over the
total implants performed was scored during each observation. The
potency of angiogenic activity was evaluated on the basis of the
number and growth rate of newly formed capillaries, and an angio-
genic score was calculated [vessel density ´ distance from limbus]
as previously reported (Ziche et al, 1994, 1997).
Xenograft experiments in BALBc Nu/Nu mice
A total of 107 MCF-7 cells were co-xenografted with 107 MDA-
435S cells, exactly as described (Zhang et al, 1995). Xenograft
experiments were performed in accordance with the British Home
Office Animals (Scientific Procedures) Act of 1986. Tumour
cytosols were prepared according to Smith et al (1993).
Immunohistochemistry
Immunohistochemistry employed the VG1, anti-VEGF antibody
that efficiently stains VEGF in paraffin sections (Turley et al,
1998). Immunohistochemistry was performed as described (Turley
et al, 1998). Transfected cells were fixed, paraffin-embedded and
stained exactly as for the tissues.
Statistical analysis
P-values were calculated by the Mann–Whitney U-test
(two-tailed).
RESULTS
Transfection of VEGF165 and VEGF189 into MCF-7
breast carcinoma cells
Plasmid containing the coding sequence for either VEGF165 or
VEGF189 under the transcriptional control of the CMV promoter
was transfected into MCF-7 breast carcinoma cells. VEGF-
expressing clones were initially identified by overexpression of
VEGF165 or VEGF189 mRNA (data not shown). Conditioned
media from mRNA overexpressing clones was then screened for
VEGF protein expression by ELISA. Before collecting media for
ELISA, the cells were treated with media containing 1 mM
suramin to release VEGF bound to heparin-like molecules on the
cell surface into the media. Control assay of recombinant VEGF
spiked with suramin showed that its presence did not interfere with
the ELISA assay. Clones were chosen that, as far as possible,
expressed similar amounts of the protein (Table 1), although the
highest expressing 189 clone obtained expressed somewhat less
protein than did transfectants of the other two isoforms.
Immunohistochemistry of fixed, paraffin-embedded
transfectants
Figure 1 shows immunostaining of control and transfected MCF-7
cells after fixation and paraffin embedding. Control and VEGF121
transfectants were negative. VEGF165 transfectants showed
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demonstrated nuclear staining. We have shown by Western
analysis that the VG1 antibody recognizes VEGF121, VEGF165
and VEGF189 (Turley et al, 1998). It follows from this that it
should recognize all three isoforms in paraffin sections equally.
Effect of VEGF121 and VEGF165 on the growth of
microvascular endothelial cells in vitro
Human dermal microvascular endothelial cells were stimulated
with recombinant VEGF121 and VEGF165. Figure 2 shows that
the in vitro growth stimulatory activity of these two isoforms was
similar.
Effect of VEGF expression on MCF-7 cell growth in vitro
To compare the growth rates of the clones in vitro, cells were
seeded at a density of 25 000 per well in quadruplicate in a 
24-well plate. Cells were counted 1 week later as follows: MCF-
7NEO 33 800 ± 1255, MCF-7VEGF121 33 500 ± 1480, MCF-
7VEGF165 34 025 ± 895 and MCF-7VEGF189 33 200 ± 1055.
We note that the growth rate of the cells appears unusually slow.
This is not due to an intrinsically slow rate of growth but because
these early passage MCF-7 cells undergo sustained apoptosis
when cultured in vitro. The apoptosis is a feature of the early but
not late passage cells. It is, however, clear that there was no signifi-
cant difference in the increase in viable cell numbers in vitro
between any of the four clones (P > 0.05).
Rabbit corneal angiogenesis assays
Figure 3 shows that the MCF-7VEGF121 cells elicit a more rapid
and extensive angiogenic response in the rabbit corneal angio-
genesis assay than do control MCF-7NEO cells. In contrast,
MCF-7VEGF165 and MCF-7VEGF189 showed a much weaker
induction of angiogenesis in the assay. The response was more
similar to that shown by control MCF-7NEO cells. More striking
was the time taken to elicit a response following implantation.
Thus, only the MCF-7VEGF121 cells elicited a rapid response,
with detectable angiogenesis occurring on days 5–7 post implanta-
tion. In contrast, the other clones showed no response until at least
20 days post implantation. Nevertheless, between days 22 and 27
the response to MCF-7VEGF165 and MCF-7VEGF189 was
greater than that in the control MCF-7NEO cells.
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Table 1 VEGF production by MCF-7 cells and transfectants in vitro
determined by ELISA of conditioned media
CM – S CM + S Lysate
MCF-7wild-type 3.1 6.0 0
MCF-7NEO 4.7 8.8 0
MCF-7VEGF121 97.9 97.0 6.5
MCF-7VEGF165 46.1 64.1 17.5
MCF-7VEGF189 7.6 20.7 1.4
VEGF protein is given in ng ml–1. Assays were carried out in quadruplicate.
The +S conditioning/media contained 1 mM suramin to release VEGF165 and
VEGF189 from the cell surface. CM, conditioned media. S, suramin.
WT 121
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Figure 1 Immunohistochemical staining of fixed, paraffin-embedded MCF-7
cell transfectants. All transfectants were treated identically (in parallel) in the
same experiment to rule out artificial immunostaining of e.g. the nucleus
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Figure 2 Effect of recombinant VEGF121 and VEGF165 on the growth of
human dermal microvacular endothelial cells in vitro (n = 2, ± s.d.). Control
(l l), VEGF121 (l) and VEGF165 (n n)Xenograft of MCF-7 transfectants with MDA-435S
breast carcinoma cells into BALBc Nu/Nu athymic mice
We have previously shown that early passage (< 65) MCF-7 cells
are weakly tumorigenic when xenografted into nude mice,
showing poor tumour take. To circumvent this problem we
routinely co-xenograft our MCF-7 transfectants with the tumori-
genic MDA-435S cells. Co-xenografting gives rise to a mixed
tumour with islands of oestrogen receptor (ER)-positive MCF-7
cells growing within the ER-negative MDA-435S cells. This
mimics the situation frequently found in primary human breast
carcinomas where there is often a mixed population of ER-positive
and ER-negative cells within the tumour. We have found this
model to consistently give highly reproducible tumour growth.
Thus, the four transfectants were co-xenografted with an equal
number of MDA-435S cells into nude mice. Figure 4 shows the
result of a typical experiment. It is seen that the MCF-7VEGF121
cells form more rapidly growing tumours than do wild-type cells.
In contrast, VEGF165 or VEGF189 expression had a far less
marked effect on tumorigenesis. In fact, VEGF189 expression
showed no effect on tumour growth compared to controls, whereas
VEGF165 did enhance tumor growth but only 50 days post
xenograft. Table 2 gives the VEGF content of tumours determined
by ELISA of tumour cytosols.
DISCUSSION
This study has aimed to compare the effects of the most commonly
expressed isoforms of VEGF on tumorigenesis in a mouse model.
We have used early passage MCF-7 cells because these are known
to produce low levels of only a few angiogenic factors, including
VEGF (Zhang et al, 1995). VEGF165 and VEGF189 were inde-
pendently transfected into human MCF-7 breast carcinoma cells
and clones selected that, as far as possible, expressed comparable
amounts of the VEGF protein by ELISA. Selected clones were
then examined in the rabbit corneal angiogenesis assay and in a
mouse xenograft model.
Prior to the in vivo studies, the transfectants were fixed,
paraffin-embedded and immunostained for VEGF. The 121 trans-
fectant did not immunostain; however, there was much VEGF in
the conditioned media from the ELISA analysis, even in the
absence of suramin. We conclude that the 121 isoform is freely
released from the MCF-7 cells. In contrast, immunostaining of the
165 transfectant showed there to be a substantial amount of
VEGF165 retained in the MCF-7 cell cytoplasm. This was
supported by an ELISA of the cell lysate (Table 1) that showed
17.5 ng ml–1 of 165 versus 6.5 ng ml–1 121 and 1.4 ng ml–1 of 189
respectively. Nevertheless, ELISA of the 165 isoform in suramin-
containing conditioned medium confirmed that substantial
amounts of VEGF165 were secreted. Retention of VEGF165 in
the Golgi apparatus has been reported in other transfectants (Park
et al, 1993). Although nuclear staining was seen with the 189
transfectant, again substantial VEGF was released in vitro by the
cells (20.7 ng mg–1 in the conditioned medium of suramin-treated
cells, Table 1). Conditioned media from each of the transfectants
was shown to have greater growth stimulatory activity on human
dermal microvascular endothelial cells than did that from control
empty vector transfectants (data not shown). Thus, we conclude
that in each case the VEGF made by the transfectant is active.
Figure 2 shows that VEGF121 and VEGF165 have similar growth
stimulatory activity in vitro.
The rabbit corneal assay showed that the secretion of the
VEGF121 isoform gave rise to much greater angiogenic activity
than did secretion of the 165 or 189 isoforms. Consistent with this
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Table 2 VEGF content of xenografted tumours determined by ELISA of
homogenates
VEGF (pg mg–1 protein)
MCF-7 neo 255 ± 42.5 (n = 7)
MCF-7VEGF121 308.5 ± 42.5 (n = 5)
MCF-7VEGF165 13 501 ± 106.4 (n = 9)
MCF-7VEGF189 255 ± 53.2 (n = 8)
n = number of tumours sampled. All tumours sampled were of very similar
size.
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Figure 3 Angiogenic activity of control MCF-7 cells and the VEGF
expressing MCF-7 cell transfectants in the rabbit corneal assay.
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Figure 4 Growth of MCF-7 xenografts in BALBc nu/nu athymic mice. n = 10
for each group ± s.d. The tumour volume in mm3 is given (length ´ width2)/2.
A similar result was seen for 4 out of 5 experimentsit was found that the 121 isoform enhanced tumorigenesis much
more so than did expression of the 165 isoform, although the latter
did enhance tumour growth 50 days post xenograft. Expression of
the VEGF189 isoform had no effect on tumour growth. It is known
that the different isoforms bind to the VEGF receptors flt-1 and
KDR with equal affinity and that they have the same growth stim-
ulating activity but that they differ in their affinity for heparin or
heparin-like molecules. It is postulated that it is this different
affinity for heparin like molecules that leads to the different effects
on tumourigenenesis. The in vitro data show that VEGF165 and
VEGF189 but not VEGF121 are tightly bound to the extracellular
surface of the MCF-7. Thus, VEGF165 and VEGF189 are released
from the cell surface in significant amounts only on treatment with
a heparin competitor such as suramin (Table 1). If the same were to
happen in vitro it would explain the observations. Thus, in the
rabbit cornea, VEGF121 freely diffuses through the cornea away
from the MCF-7 cell implant toward the vascular limbus, where it
initiates angiogenesis. Compare this to the 165 and 189 isoforms
which remain bound to the surface of the MCF-7 cells and take 20
days post implant to reach the vascular limbus. It is notable that
when the angiogenic response to VEGF165 or VEGF189 does
finally occur it is as strong and rapid as that to VEGF121, consis-
tent with the isoforms being equipotent in endothelial growth
factor activity (Figure 2). The response to the 165 and 189 trans-
fectants was similar despite the greater release of VEGF165 than
VEGF189.
Several growth factors, thought to be extracellularly acting,
have subsequently been shown to localise to the nucleus (e.g. basic
fibroblast growth factor (bFGF) (Coltrini et al, 1995) the related
int-2 (Acland et al, 1990) and interferon-g (Bader and Wiezerbin,
1994). The biological function of this localization has remained
unknown, particularly in the light of the fact that the bFGF trans-
fectants show no known phenotypic differences (Coltrini et al,
1995). In the case of bFGF and int-2 the subcellular fate of the
protein was shown to depend on the choice of initiation codon.
VEGF is different in that the subcellular localisation is determined
not by choice of initiation codon but by differential splicing. A
strong consensus nuclear localisation signal was identified in exon
6a of VEGF (Table 3) (Robbins et al, 1991) and only isoforms
containing this exon (145, 189 and 206) will have the nuclear
localization signal. There are no nuclear localization signals in any
of the other growth factors showing sequence homology to VEGF
(i.e. VEGF-B, C, D, E or PLGF, PDGF-A and PDGF-B) (data not
shown).
The overall conclusion of this study is that the 121 shows a
stronger induction of tumorigenesis than do the other commonly
expressed 165 and 189 isoforms in vivo. This is particularly signif-
icant in view of the fact that the 121 isoform has been shown to
predominate in primary human breast carcinomas (Relf et al,
1997). It also has important implications for clinical applications
in which the stimulation of angiogenesis is the desired objective,
e.g. ischaemic limb re-vascularization. As VEGF121 is freely
diffusible, its use in such studies has clear advantages. The reason
for selective nuclear localisation of VEGF189 is, as for other
factors that show a similar effect, completely unclear.
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